Besides inhibition of AChE, several different strategies have been used in the development of drugs able to target other mechanisms involved in the pathogenesis of AD-like amyloid-β (Aβ) peptide deposits, oxidative stress, dyshomeostasis of biometals, and hyperphosphorylated tau protein [3]. This evidence concerns the gene ACHE and Alzheimer disease.